Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLC

Video

Rodolfo Bordoni, MD, discusses the utility of ​atezolizumab in the adjuvant setting in non–small cell lung cancer.

Rodolfo Bordoni, MD, medical oncologist, director of clinical research, leader, Phase I Clinical Trials Program, Georgia Cancer Specialists, discusses the utility of ​atezolizumab (Tecentriq) in the adjuvant setting in non–small cell lung cancer (NSCLC).

Atezolizumab demonstrated efficacy when used as adjuvant therapy for patients with NSCLC who underwent resection and platinum-based chemotherapy, Bordoni says. However, this is only the case when patients have PD-L1–positive disease on at least 1% of tumor cells; PD-L1–negative patients did not respond to adjuvant atezolizumab, Bordoni explains. 

Moreover, on October 15, 2021, the FDA approved adjuvant atezolizumab for patients with stage II to IIIA NSCLC following resection and platinum-based chemotherapy whose tumors have PD-L1 expression on at least 1% of tumors cells, as determined by an FDA-approved test. 

Moreover, the role of adjuvant therapy is an area that needs additional research, Bordoni continues. Several clinical trials are being conducted evaluating immunotherapy alone or in combination regimens, and these data are highly anticipated, Bordoni concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD